DIET & NUTRITION 
PATIENT EDUCATION 
OBESITY/WEIGHT MANAGEMENT 
EXERCISE/TRAINING 
LEGAL MATTERS 
GUIDELINES/RECOMMENDATIONS The Sartor, et al randomized controlled trial (RCT), which demonstrated a significant improvement in radiographic progression-free survival and overall survival (OS) in patients with PSMA-positive mCRPC, served as the foundation for the 177Lutetium-PSMA-617 (177Lu-PSMA-617) March 2022 approval. The availability of this theranostic option served as a compelling argument for revising the 2014 proposal to include a prompt endorsement of 177Lu-PSMA-617. The mCRPC recommendations are now being updated completely.
Peer-influenced content. Sources you trust. No registration required. This is HCN.